Risperdal Marketing Settlement Prevents Reprint Distribution Without sNDA
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J’s agreement with state AGs, which involves payments totaling $181 million, sets a number of restrictions on the company’s marketing practices for atypical antipsychotics that will be in effect for five years.
You may also be interested in...
J&J Challenges Risperdal Penalty As First Amendment Violation
In case that could impact use of state unfair trade practices statutes, Janssen seeks Supreme Court review of South Carolina’s $124 million judgment for Risperdal labeling and Dear Doctor letter.
FDA Warning Letter Is Inadmissible Hearsay, Arkansas Supreme Court Says In Tossing J&J Judgment
Court throws out $1.2 billion award to the state of Arkansas over Risperdal promotions.
J&J Risperdal Off-Label Settlement Includes Exec Pay Recoupment Provision
Janssen subsidiary pleads guilty as part of $2.2 billion deal that also requires audits of sales rep compensation.